Radiance Biopharma Signs Exclusive License For 'First In Class' Nano Antibody ADC
Sept 3 (Reuters) -
RADIANCE BIOPHARMA SIGNS EXCLUSIVE LICENSE FOR 'FIRST IN CLASS' C-MET/EGFR TARGETED NANO ANTIBODY ADC
RADIANCE BIOPHARMA: TO PAY NOVATIM UPFRONT PAYMENT OF USD$15 MILLION, UP TO $150 MILLION IN POTENTIAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS
RADIANCE BIOPHARMA: WILL PAY NOVATIM OVER $1 BILLION IN POTENTIAL COMMERCIAL MILESTONE PAYMENTS
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Is Meta Platforms Stock a Smart Buy Ahead of Q1 2026 Earnings? Unpacking AI Growth and Investment Potential

Tradingkey








